Monatshefte für Chemie - Chemical Monthly

, Volume 148, Issue 1, pp 63–68 | Cite as

A simplified and scalable synthesis of artesunate

  • Armin Presser
  • Andrea Feichtinger
  • Silke Buzzi
Open Access
Original Paper


An efficient and economically viable approach for the large-scale conversion of artemisinin into the antimalarial frontline drug artesunate was developed. This advanced synthesis includes an NaBH4-induced reduction, followed by an esterification with succinic anhydride under basic conditions. The entire conversion follows the principles of green chemistry, i.e., application of reusable solvents.

Graphical abstract


Antimalarial Peroxides Natural products Reductions Green chemistry 


Malaria, caused by parasitic protozoans of the Plasmodium type, still remains a life-threatening disease with about 600,000 death cases each year, with many of them being children under 5 years. The sesquiterpene endoperoxide artemisinin (1) [1, 2], is the lead component of the so-called artemisinin combination therapies (ACTs), which is currently the most valuable weapon in the fight against this disease. Several easily accessible artemisinin derivatives, including dihydroartemisinin (DHA, 2) and artesunate (3), exhibit potent antimalarial activity against drug-resistant malaria strains [3, 4, 5]. In addition, they also show remarkable activities against other parasites and various cancer types [4, 6].

Artemisinin was discovered in the 1970s as a result of an extensive screening of Chinese herbal extracts in the search of new antimalarial agents [7]. Currently, the primary method for the production of artemisinin is the isolation from dried leaves of the plant Artemisia annua. Shortcomings of existing processes are poor yields and environmental pollution [8]. Furthermore, the global supply of this life-saving drug exclusively from natural sources remains highly limited. As a result, several novel approaches for large-scale production of artemisinin have been developed [9, 10, 11, 12, 13].

ACT medications rely not only on the procurement of artemisinin, also the derivatives DHA (2, also known under its INN identification artenimol) and artesunate (3) became frontline drugs due to stronger activity and improved bioavailability compared to the parent compound [1, 14]. The transformation of artemisinin into artesunate was commonly realized by a two-step process involving the reduction with NaBH4 [15, 16, 17, 18, 19], KBH4 [20, 21] or diisobutylaluminium hydride (DIBAL) [22, 23], followed by esterification using succinic anhydride [24, 25]. However, these syntheses described in the scientific literature are not suitable for an industrial large-scale process because they require very low temperature, highly expensive or toxic reagents and solvents or provide only moderate yields. Recently, some continuous flow protocols for the preparation of 2 and 3 were published [26, 27, 28]. Flow protocols have some technical advantages over batch protocols. However, batch processing still dominates the manufacturing of pharmaceuticals today.

On the basis of our earlier studies sponsored by Medicines for Malaria Ventures (MMV) [29], we report herein a facile and scalable synthetic route for the preparation of dihydroartemisinin (2) and artesunate (3) from 1 in high yields following the principles of green chemistry, i.e., the minimization of waste, avoidance of toxic solvents, and elimination of unnecessary steps.

Results and discussion

Our initial work started with the well-described reduction of artemisinin with NaBH4 in methanol. THF or dioxane were also used as solvents [30]; however, because of ecological and economic reasons, the use of these solvents was ruled out [31, 32, 33]. DIBAL in CH2Cl 2 seems to be a superior reagent for the conversion of artemisinin to DHA [23], but it is more expensive and requires extremely low temperature. The also known procedure with KBH4 in the presence of a phase-transfer catalyst [20] shows some inconsistencies and contains a rather hazy experimental part.

After assessing diverse instructions from the literature, we determined the most suitable conditions for the reduction of artemisinin: first, we identified the amount of NaBH4 required for the complete transformation. As a consequence of the competing methanol-induced solvolysis, a certain excess of the reagent is definitely required. It is known that the instability of NaBH4 in MeOH can be overcome by the addition of a base [34], but the extreme vulnerability of DHA towards small amounts of strong bases [21] excludes this approach. Apparently, the application of a lower reaction temperature leads to a slower decomposition of NaBH4 by MeOH [21]. As a consequence, the reaction time has to be kept short, and the reaction temperature kept as low as possible. Due to the decrease of the reaction temperature, the excess of NaBH4 could be considerably reduced as compared to the published instructions. However, a contamination of the reagent with traces of strong bases will also have a negative impact on the yield.

The best results were achieved when 2.5 equiv. of NaBH4 were added to a suspension of approx. 0.6 M artemisinin in MeOH at 0–5 °C over 30 min and a total reaction time of 1 h (Scheme 1). Two different types of NaBH4, powder and granulate, were tested. Even though the yields are identical, the use of granulated material is preferred because the production of toxic dust during handling is minimized. Subsequently, the work-up conditions were optimized. After destroying the excess of NaBH4 with acetic or hydrochloric acid, DHA is usually precipitated by the addition of water. Through this procedure, DHA could be obtained in satisfactory yields (79–89%) as published previously [16, 19, 21]. In an alternative strategy, the yield of DHA could be further enhanced by neutralization with 30% acetic acid/MeOH at 0–5 °C, concentration, and multiple extraction of the white residue using Et-OAc. Evaporation under reduced pressure provided 2 as a white crystalline powder in 98% yield, which can be used in the next step without further purification. To reduce the large consumption of Et-OAc, the solvent was distilled and reused.

Bulk solid DHA results solely as β-epimer of the lactol hemiacetal [35]. Addition of CDCl3 provides a solution consisting exclusively of 2 β, which equilibrates gradually to a 1:1 mixture of 2 α and 2 β. The epimerization is clearly indicated by arising signals at 5.39 ppm (H-12α) and 4.75 ppm (H-10α) in the 1H NMR spectrum (see Fig. 1). The equilibrium ratio is depending on the solvent [36]: in CH3CN/H2O which we used for HPLC analysis, the relation of 2 α and 2 β is 3:1.
Fig. 1

1H NMR of DHA (2): immediately after dissolution (a) and after 12 h (b)

Acylation of DHA (2) to artesunate (3) was first realized with succinic anhydride in the presence of pyridine as a base/solvent [24]. The use of catalytic DMAP was also reported [37] with a yield of 65%. Aside from Chinese publications, there exist only marginal instructions [25] for the preparation of 3 so far. Also, a patent specification with Et3N as base in acetone, THF, or dioxane promising yields up to 97% [38] was not reproducible [36]. Pharmaceutically approved artesunate is an α-linked dihydroartemisinin hemisuccinate. It was reported that acylation of DHA in alkaline media led almost exclusively to α-configured derivatives [35, 39]. An obvious reason may be the crowded environment of the axial hydroxyl in the β-epimer or the higher stability and thermodynamically favored conformation of 2 α. The classical esterification method using acid chlorides or anhydrides in pyridine (Einhorn method) requires anhydrous conditions. In our first attempt, we replaced the originally used pyridine by Et3N and chose Et-OAc as a reusable and ecologically more acceptable solvent. A supplemental addition of DMAP as well as the usage of anhydrous solvents appeared to be negligible. To further improve the reaction conditions, we investigated the stoichiometric ratio of the reagents. As shown in Table 1, the esterification occurred almost quantitatively with a 1.4-fold excess of succinic anhydride using 0.6 equiv. of Et3N. The reaction can take place at RT or even higher temperature (up to 50 °C) without any difference in yield.
Table 1

Synthesis of artesunate with different stoichiometric ratios and temperatures


Succ. anhydr./equiv

















































Reaction conditions: dihydroartemisinin (2, 35.2 mmol), succinic anhydride and Et3N as stated above, 30 cm3 solvent; the reactions were monitored by TLC until the apparent consumption of the limiting substrate

aIsolated yield

Unfortunately, the recycling of Et-OAc by distillation leaves a water content up to 8.5% [40] which negatively affects the yield when reused solvent was applied. This difficulty was overcome by changing the reaction medium to isopropyl acetate. Because of the lower moisture content (1.5% determined via Carl Fischer titration), even after recycling of the solvent, artesunate was obtained in the same excellent yields. 1H NMR spectroscopic analyses confirmed that exclusively α-artesunate was formed; the large trans-diaxial coupling of H-10 at 5.67 ppm (J 10,9 = 9.7 Hz) pinpoints the requested configuration at C-10.


In summary, we report on the development of an advanced synthetic route for the conversion of the natural product artemisinin into semisynthetic artesunate by NaBH4-induced reduction and subsequent esterification under basic conditions as pivotal steps. Using our synthetic approach, feasibility and scalability of the synthesis can be dramatically improved while the overall yield remains among the best so far documented. This procedure should favorably complement the existing routes and may represent an additional entry to the production of artesunate at low costs.


Melting points were obtained on a digital melting point apparatus (Electrothermal IA 9200). The NMR spectra were measured on a Varian Unity Inova 400 instrument (at 298 K) using 5-mm tubes. Chemical shifts were given in parts per million (ppm); the tetramethylsilane (TMS) resonance (0.00 ppm) was used as internal standard. Coupling constants (J) were reported in Hertz (Hz). 1H and 13C resonances were assigned using 1H, 1H and 1H, 13C correlation spectra. 1H and 13C resonances are numbered as given in the formulae. The signals marked with an asterisk are interchangeable. The IR spectra were recorded on an ALPHA FT-IR-spectrometer (Bruker). Optical rotation was determined on a P-2000 polarimeter (Jasco). The water content of the solvents was quantified via Carl Fischer titration on a TitroLine 7500 KF (SI Analytics). HPLC separations were performed on a Merck Hitachi HPLC apparatus D6000A consisting of a pump L6200 and UV–Vis-detector L4250. Diastereomer separation was achieved using a LiChrospher® 100 RP–18 (5 μm, 125 × 3 mm, Merck) HPLC column, operated at 30 °C. Each 10-min chromatographic run was carried out at a flow rate of 0.5 cm3/min with an isocratic mobile phase consisting of acetonitrile (20%) and Millipore water (80%). Runtime was 10 min and detection wavelength was 224 nm. The purity of artesunate was checked by HPLC analysis performed on an Agilent 1200 series equipped with an autosampler, a quaternary pump system and a photodiode array detector. An Agilent Zorbax SP-C18 column (particle size 3.5 μm; 2.1 × 150 mm with guard cartridge) was used at a flow rate of 0.30 cm3/min. The chromatographic method was performed with a gradient of acetonitrile (A) in Millipore water (B), both with each 0.1% HCOOH, from 10 to 90% A in B within 20 min, then to 100% A within 5 min followed by returning to starting conditions within 1 min and re-equilibration for 8 min. 10 mm3 of sample was injected and detection was done at 220 nm. Materials: TLC was carried out on Merck TLC plates (silica gel 60 F 254 0.2 mm, 200 × 200 mm). TLCs were visualized by spraying with cerium(IV) sulfate/ammonium molybdate and subsequent heating with a heat gun. The solvents were concentrated by rotary evaporation below 50 °C. Purity and homogeneity of compounds were assessed by TLC and HPLC methods.

(3R,5aS,6R,8aS,9R,10S,12R,12aR)-Decahydro-3,6,9-trimethyl-3,12-epoxy-12H-pyrano[4,3-j][1,2]benzodioxepin-10-ol (dihydroartemisinin, 2)

Artemisinin (10.0 g, 35.4 mmol) was suspended in 60 cm3 MeOH and cooled in an ice bath to 0–5 °C. To the suspension, 3.35 g of NaBH4 (88.5 mmol) was added in small portions over a period of 30 min. After the addition of NaBH4 was complete, the reaction was allowed to reach ambient temperature and was stirred vigorously under Ar until the TLC showed complete consumption of 1 (~30 min). The mixture was neutralized (pH 5–6) with 30% AcOH/MeOH, concentrated under reduced pressure and finally lyophilized. The white residue was extracted with Et-OAc several times. The combined Et-OAc extracts were filtered and evaporated to dryness to give 9.87 g (98%) DHA as a white crystalline powder, which can be used in the next step without further purification. R f = 0.46 (CH2Cl2:MeOH = 20:1), m.p.: 150–151 °C (Ref. [41], 152–153 °C). The spectroscopic data were found to be identical with the ones described in Refs. [41, 42, 43].

(3R,5aS,6R,8aS,9R,10S,12R,12aR)-Decahydro-3,6,9-trimethyl-3,12-epoxy-12H-pyrano[4,3-j][1,2]benzodioxepin-10-ol, hydrogen succinate (artesunate, 3)

A solution of 4.93 g succinic anhydride (49.2 mmol) in 30 cm3 isopropyl acetate was treated under Ar with 2.94 cm3 Et3N (21.1 mmol). To this solution, 10.0 g of 2 (35.2 mmol) was successively added over a period of 30 min and the mixture was stirred at ambient temperature for 4 h. Then, it was quenched with H2O and H2SO4 (2 N) until pH 5 was reached and stirred for a few minutes to achieve phase separation. The aqueous phase was extracted thoroughly with isopropyl acetate and the combined organic layers were concentrated under reduced pressure providing almost pure α-artesunate (impurities <1%) as fine white needles. Yield 12.7 g (94%).

A batch size over 50 g DHA requires a modified work-up: After quenching with a small amount of H2O and neutralization with H2SO4 (2 N), the mixture was diluted with isopropyl acetate and heated to 50 °C to dissolve precipitated 3. The organic layer was washed with warmish H2O and concentrated under reduced pressure providing α-artesunate as described above. R f = 0.27 (CH:Et-OAc = 1:1), m.p.: 131–133 °C (MeOH:H2O = 1:2) (Ref. [39], 135 °C). The spectroscopic data were found to be identical to the ones described in Refs. [39, 44]. Although the crystal structure of 3 is already known [39], to the best of our knowledge, a complete assignment of the NMR signals has never been published: 1H NMR (400 MHz, DMSO-d 6 ): δ = 5.67 (d, J = 9.7 Hz, 1H, H-10), 5.56 (s, 1H, H-12), 2.63–2.58 (m, 2H, H-18′, H-19′), 2.53–2.48 (m, 2H, H-18″, H-19″), 2.35–2.23 (m, 1H, H-9), 2.18 (td, J = 13.9, 3.9 Hz, 1H, H-4′), 2.00 (dt, J = 13.9, 3.9 Hz, 1H, H-4″), 1.81 (dq, J = 10.3, 3.5 Hz, 1H, H-5′), 1.67–1.61 (m, 1H, H-8′), 1.64–1.57 (m, 1H, H-7′), 1.58–1.51 (m, 1H, H-8a), 1.48–1.41 (m, 1H, H-8″), 1.47–1.37 (m, 1H, H-6), 1.36–1.27 (m, 1H, H-5″), 1.29 (s, 3H, H-13), 1.19 (dd, J = 11.3, 6.4 Hz, 1H, H-5a), 1.02–0.88 (m, 1H, H-7″), 0.89 (d, J = 6.4 Hz, 3H, H-14), 0.77 (d, J = 7.1 Hz, 3H, H-15) ppm.; 13C NMR (100 MHz, DMSO-d 6 ): δ = 173.7 (C-20), 171.5 (C-17), 104.0 (C-3), 92.2 (C-10), 91.1 (C-12), 80.3 (C-12a), 51.6 (C-5a), 45.0 (C-8a), 36.4 (C-4, C-6), 34.2 (C-7), 32.1 (C-9), 29.2* (C-18), 28.9* (C-19), 26.0 (C-13), 24.7 (C-5), 21.5 (C-8), 20.5 (C-14), 12.2 (C-15) ppm.



Open access funding provided by University of Graz. We are grateful to Priv.-Doz. W. Schuehly for discussions, to the MMV and the German Medical Aid Organization action medeor e.V. for financial support.


  1. 1.
    Chang Z (2016) Sci China Life Sci 59:81CrossRefGoogle Scholar
  2. 2.
    Edikpo NJ, Adikwu E (2013) Br J Pharmacol Toxicol 4:241Google Scholar
  3. 3.
    Ploypradith P (2004) Acta Trop 89:329CrossRefGoogle Scholar
  4. 4.
    Ansari MT, Saify ZS, Sultana N, Ahmad I, Saeed-Ul-Hassan S, Tariq I, Khanum M (2013) Mini Rev Med Chem 13:1879CrossRefGoogle Scholar
  5. 5.
    Visser BJ, van Vugt M, Grobusch MP (2014) Expert Opin Pharmacother 15:2219CrossRefGoogle Scholar
  6. 6.
    Liu Y-X, Wu W, Liang Y-J, Jie Z-L, Wang H, Wang W, Huang Y-X (2014) Molecules 19:15058CrossRefGoogle Scholar
  7. 7.
    Tu Y (2011) Nat Med 17:1217CrossRefGoogle Scholar
  8. 8.
    Malwade CR, Qu H, Rong B-G, Christensen LP (2013) Ind Eng Chem Res 52:7157CrossRefGoogle Scholar
  9. 9.
    Chen H-J, Han W-B, Hao H-D, Wu Y (2013) Tetrahedron 69:1112CrossRefGoogle Scholar
  10. 10.
    Corsello MA, Garg NK (2015) Nat Prod Rep 32:359CrossRefGoogle Scholar
  11. 11.
    Turconi J, Griolet F, Guevel R, Oddon G, Villa R, Geatti A, Hvala M, Rossen K, Goller R, Burgard A (2014) Org Process Res Dev 18:417CrossRefGoogle Scholar
  12. 12.
    Amara Z, Bellamy JFB, Horvath R, Miller SJ, Beeby A, Burgard A, Rossen K, Poliakoff M, George MW (2015) Nat Chem 7:489CrossRefGoogle Scholar
  13. 13.
    Burgard A, Gieshoff T, Peschl A, Hoerstermann D, Keleschovsky C, Villa R, Michelis S, Feth MP (2016) Chem Eng J 294:83CrossRefGoogle Scholar
  14. 14.
    Cui L-W, Su X-Z (2009) Expert Rev Anti Infect Ther 7:999CrossRefGoogle Scholar
  15. 15.
    Lin AJ, Klayman DL, Milhous WK (1987) J Med Chem 30:2147CrossRefGoogle Scholar
  16. 16.
    Brossi A, Venugopalan B, Dominguez Gerpe L, Yeh HJC, Flippen-Anderson JL, Buchs P, Luo XD, Milhous W, Peters W (1988) J Med Chem 31:645CrossRefGoogle Scholar
  17. 17.
    Shrimali M, Bhattacharya AK, Jain DC, Bhakuni RS, Sharma RP (1998) Indian J Chem Sect B Org Chem Incl Med Chem 37B:1161Google Scholar
  18. 18.
    Ferreir JFS, Janick J (1996) Phytochemistry 41:97CrossRefGoogle Scholar
  19. 19.
    Liu Y, Liu Z, Shi J, Chen H, Mi B, Li P, Gong P (2013) Molecules 18:2864CrossRefGoogle Scholar
  20. 20.
    Wei G-F, Liao X-J, Pan G-Y, Huang Z-L, Cheng J-S, He Y-C (2010) J Nat Prod 3:161Google Scholar
  21. 21.
    Boehm M, Fuenfschilling PC, Krieger M, Kuesters E, Struber F (2007) Org Process Res Dev 11:336CrossRefGoogle Scholar
  22. 22.
    Ma J, Katz E, Kyle DE, Ziffer H (2000) J Med Chem 43:4228CrossRefGoogle Scholar
  23. 23.
    Avery MA, Mehrotra S, Johnson TL, Bonk JD, Vroman JA, Miller R (1996) J Med Chem 39:4149CrossRefGoogle Scholar
  24. 24.
    China Cooperative Research Group on Qinghaosu and Its Derivatives as Antimalarials (1982) J Tradit Chin Med 2:9Google Scholar
  25. 25.
    Chekem L, Wierucki S (2007) Phytotherapie 5:90CrossRefGoogle Scholar
  26. 26.
    Fan X, Sans V, Yaseneva P, Plaza DD, Williams J, Lapkin A (2012) Org Process Res Dev 16:1039CrossRefGoogle Scholar
  27. 27.
    Gilmore K, Kopetzki D, Lee JW, Horvath Z, McQuade DT, Seidel-Morgenstern A, Seeberger PH (2014) Chem Commun 50:12652CrossRefGoogle Scholar
  28. 28.
    Yaseneva P, Plaza D, Fan X, Loponov K, Lapkin A (2015) Catal Today 239:90CrossRefGoogle Scholar
  29. 29.
    Buzzi S, Presser A, von Freyhold M (2007) Determining a viable protocol for the derivatisation of artemisinin into dihydroartemisinin and into artesunate. A report commissioned by MMV.
  30. 30.
    Bhakuni RS, Kahol AP, Singh T, Khanuja SPS (2004) Single-pot conversion of artemisinin to artesunic acid. Int. Pat. WO 2004/050661 A1, Jun 17, 2004; (2004) Chem Abstr 141:54501Google Scholar
  31. 31.
    Prat D, Hayler J, Wells A (2014) Green Chem 16:4546CrossRefGoogle Scholar
  32. 32.
    Prat D, Wells A, Hayler J, Sneddon H, McElroy CR, Abou-Shehada S, Dunn PJ (2016) Green Chem 18:288CrossRefGoogle Scholar
  33. 33.
    Alder CM, Hayler JD, Henderson RK, Redman AM, Shukla L, Shuster LE, Sneddon HF (2016) Green Chem 18:3879CrossRefGoogle Scholar
  34. 34.
    Jensen EH (1954) A study on sodium borohydride. Nyt Nordisk Forlag Arnold Busck A/S, CopenhagenGoogle Scholar
  35. 35.
    Luo XD, Yeh HJC, Brossi A, Flippen-Anderson JL, Gilardi R (1984) Helv Chim Acta 67:1515CrossRefGoogle Scholar
  36. 36.
    Haynes RK (2006) Curr Top Med Chem 6:509CrossRefGoogle Scholar
  37. 37.
    Li Y, Yu P, Chen Y, Ji R (1982) Huaxue Xuebao 40:557Google Scholar
  38. 38.
    Ognyanov IV, Konakchiev AN, Haenni R (1996) Process for the production of dihydroartemisinin hemisuccinate. Eur. Pat. EP 736535 A1, Oct 9, 1996; (1996) Chem Abstr 125:301268Google Scholar
  39. 39.
    Haynes RK, Chan H-W, Cheung M-K, Lam W-L, Soo M-K, Tsang H-W, Voerste A, Williams ID (2002) Eur J Org Chem:113Google Scholar
  40. 40.
    Merriman RW (1913) J Chem Soc. Trans 103:1790Google Scholar
  41. 41.
    Njogu PM, Gut J, Rosenthal PJ, Chibale K (2013) ACS Med Chem Lett 4:637CrossRefGoogle Scholar
  42. 42.
    Pathak AK, Jain DC, Sharma RP (1995) Indian J Chem Sect B Org Chem Incl Med Chem 34B:992Google Scholar
  43. 43.
    Sy L-K, Hui S-M, Cheung K-K, Brown GD (1997) Tetrahedron 53:7493CrossRefGoogle Scholar
  44. 44.
    Nyadong L, Harris GA, Balayssac S, Galhena AS, Malet-Martino M, Martino R, Parry RM, Wang MD, Fernandez FM, Gilard V (2009) Anal Chem 81:4803CrossRefGoogle Scholar

Copyright information

© The Author(s) 2016

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (, which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

Authors and Affiliations

  1. 1.Institute of Pharmaceutical SciencesUniversity of GrazGrazAustria

Personalised recommendations